Rhythm drug shows sustained weight reduction in patients with brain damage-related obesity
Nov 16 (Reuters) - Rhythm Pharmaceuticals RYTM.O said on Monday its therapy for a rare form of obesity caused by brain damage showed clinically meaningful body weight reduction in patients after two years of therapy.
The company was testing setmelanotide, approved by the US FDA under the brand name Imcivree, in adult and pediatric patients with acquired hypothalamic obesity and a type of genetic obesity.
AstraZeneca AZN.L made an offer of about $10 billion to acquire Rhythm Pharmaceuticals, Reuters reported earlier this month, citing sources, as the obesity drug market has become one of the most coveted sectors in the pharmaceutical industry.
The long-term data on setmelanotide was presented at ObesityWeek 2026, in Washington, D.C.
In the trial, 142 participants, aged 4 years and older, were randomly assigned to receive setmelanotide or a placebo for the first year. After one year, all those who continued with the long-term extension received setmelanotide.
Of the 125 patients who entered the extension study, 81 completed two years of treatment, including 54 who received continuous setmelanotide and 27 who switched from placebo after the first year.
The trial showed that patients treated continuously with setmelanotide achieved an average 18.8% reduction in body mass index (BMI) after two years, while those who switched from placebo to the drug after one year saw an average 16.5% reduction, according to the data.
Acquired hypothalamic obesity is a rare neuroendocrine disease that causes excess and sustained weight gain due to injuries such as tumor growth or stroke in the brain.
The hypothalamus of the brain regulates appetite and affects how the body burns calories and stores fat.
Setmelanotide is designed to activate the MC4R pathway in the brain to reduce excessive hunger and help the body burn more energy.
The company said the safety profile of setmelanotide was generally consistent with the previous trials in acquired hypothalamic obesity patients.
In the second year, 52 of the 125 participants had treatment-related side effects, none of which was classified as serious. One death was reported and deemed unrelated to treatment, according to the company.